Search
Publications
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.
Board elections
Shape the future of EHA by taking part in our 2025 Board elections. Nominations will open on January 7, 2025. What a Board election involvesThe EHA Board is the governing body of our association.
Read moreThe European Hematology Association (EHA) Announces a New Era of Partnership with Interplan as its New Core PCO
The European Hematology Association (EHA) is delighted to announce to the conference and meeting community the outcome of its Core PCO Invitation To Tender (ITT).
Read moreEuropean Board for Accreditation in Hematology
Current committee members
Peter van den Burg, The Netherlands (Chair and ISBT representative—transfusion medicine)
Michelle Kenyon, United Kingdom (EBMT Nurses Group representative—Specialized Hematology Professional)
Fionnuala Ní Áinle, Ireland (ISTH representative—thrombosis and hemostasis)
Annalisa Ruggeri, Italy (Representative, clinical hematology)
Isabel Sanchez-Ortega, Spain (EBMT representative)
Ana Filipa Marques…
Travel Grants
Travel grant application is now closed
Travel grants are intended to support young investigators in the region; therefore, applicants should be 40 years of age or young, and are reserved for applicants from Armenia, Georgia, Iran, Azerbaijan, and Türkiye.
Clinical Research Training in Hematology
The CRTH 2025 call for applications is now closed. What is Clinical Research Training in Hematology (CRTH)?Clinical Research Training in Hematology (CRTH) provides early-career researchers with a unique, 9-month long training and mentoring experience.
Read more